GHRP-2, also called pralmorelin, is a peptide described as a growth-hormone-releasing peptide and ghrelin-receptor agonist. This page explains what it is, how it is thought to work, what the supplied human evidence can and cannot show, safety questions, dosing caveats, and how to approach access without using research-chemical vendors.
Wondering if sermorelin is right for you? Take the 3-min clinical quiz.
See if you qualify →What it is
GHRP-2 is also called pralmorelin. It is a peptide in the growth-hormone-releasing peptide family and is described as a ghrelin-receptor agonist, meaning it is designed to signal through a pathway involved in growth-hormone release.
In the supplied PubMed records, GHRP-2 appears mainly in human endocrine research: growth-hormone stimulation studies, diagnostic testing for growth-hormone deficiency, and studies of how sex hormones, exercise, and other signals affect growth-hormone release 1 5 6. That is different from proving that GHRP-2 improves body composition, athletic performance, sleep, or longevity in everyday users.
Also known as pralmorelin
The name pralmorelin is commonly used for GHRP-2 in clinical and research contexts. Many patients searching online will see both names used for the same peptide family.
Class: peptide
A peptide is a short chain of amino acids. GHRP-2 belongs to the group often called growth-hormone secretagogues, which are compounds studied for their ability to stimulate growth-hormone release in controlled testing settings 5 7.
One-line description
GHRP-2 is a growth-hormone-releasing peptide and ghrelin-receptor agonist studied in humans for endocrine responses, especially growth-hormone stimulation and related diagnostic testing 6 12.
Mechanism of action
GHRP-2 is thought to work through ghrelin-receptor signaling and growth-hormone secretagogue pathways. In plain English, it is designed to nudge the hormone system that links the hypothalamus, pituitary gland, growth hormone, and downstream signals such as IGF-1.
The supplied studies support that GHRP-2 has been used as a growth-hormone stimulus in humans. For example, researchers studied GHRP-2 alone or with other secretagogue signals to examine growth-hormone release patterns in men, women, and children 5 7 12.
Mechanism is not the same thing as clinical benefit. A compound can change a hormone signal in a lab or diagnostic test and still not be proven to improve strength, fat loss, recovery, sleep, or lifespan in real-world use.
Ghrelin-receptor agonism
Ghrelin is a hormone signal involved in hunger and growth-hormone release. GHRP-2 is described as acting on this signaling family, but the supplied records should not be read as proof that it safely changes appetite, body composition, or performance for a given person.
Growth-hormone signaling concepts
Growth hormone is released by the pituitary gland in pulses. Human studies in the supplied record set examined pulsatile growth-hormone secretion and how secretagogues interact with other signals, including growth-hormone-releasing hormone and sex-steroid conditions 7 9 10.
Why mechanism does not prove clinical benefit
A hormone response is an endpoint, not a guarantee of a patient-centered result. The records supplied for this page do not establish that GHRP-2 builds muscle, improves energy, or changes long-term health outcomes in people.
Evidence
GHRP-2 has an assigned evidence grade of A in this evidence packet. That means the record set includes two or more human randomized controlled trials, but the grade is about study quantity and design, not proof of benefit or safety.
A — two or more human randomised controlled trials. B — one human randomised trial, or two or more human clinical trials. C — human research exists, none of it randomised. D — animal or in-vitro research only; no human studies indexed. E — no trial evidence indexed in PubMed. The grade describes the quantity and design of published evidence, not whether the substance works, and not whether it is safe.
The supplied PubMed packet includes human randomized controlled trials and clinical trials involving GHRP-2, including studies of cortisol secretion, growth-hormone secretagogue control, growth-hormone-releasing hormone synergy, and diagnostic testing 2 3 7 9.
The main limitation for a patient is important: these records do not provide enough cited support here to claim that GHRP-2 improves muscle growth, fat loss, recovery, appetite control, sleep, or longevity. Individual results cannot be predicted from endocrine challenge studies.
| Question patients ask | What the supplied records can support | What they do not prove |
|---|---|---|
| Does GHRP-2 stimulate growth hormone? | Human studies used GHRP-2 as a growth-hormone stimulus or secretagogue in controlled endocrine testing 5 6. | They do not prove a personal anti-aging, bodybuilding, or recovery benefit. |
| Does GHRP-2 build muscle? | The supplied records focus on endocrine responses, not muscle-gain outcomes. | They do not establish that GHRP-2 increases lean mass or strength in everyday users. |
| Does GHRP-2 affect appetite? | GHRP-2 is described as related to ghrelin-receptor signaling. | The supplied records do not establish a predictable appetite effect for a specific person. |
| Is GHRP-2 safe? | Human trials exist in the supplied packet 1 2. | This packet does not provide enough detail to characterize long-term safety, contraindications, or rare adverse effects. |
What studies exist
| Year | Design | Study | Journal | Record |
|---|---|---|---|---|
| 1998 | Clinical trial | Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children | The Journal of clinical endocrinology and metabolism | PMID 9543135 |
| 2010 | Randomised controlled trial | Secretagogue type, sex-steroid milieu, and abdominal visceral adiposity individually determine secretagogue-stimulated cortisol secretion | European journal of endocrinology | PMID 20299490 |
| 2016 | Clinical trial | Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure | Endocrine journal | PMID 27020037 |
| 2011 | Randomised controlled trial | Regulated recovery of pulsatile growth hormone secretion from negative feedback: a preclinical investigation | American journal of physiology. Regulatory, integrative and comparative physiology | PMID 21795635 |
| 2000 | Clinical trial | Synergy of L-arginine and GHRP-2 stimulation of growth hormone in men and women: modulation by exercise | American journal of physiology. Regulatory, integrative and comparative physiology | PMID 11004017 |
| 2007 | Clinical trial | A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency | European journal of endocrinology | PMID 17609397 |
| 2013 | Randomised controlled trial | Differential pulsatile secretagogue control of GH secretion in healthy men | American journal of physiology. Regulatory, integrative and comparative physiology | PMID 23485864 |
| 1999 | Randomised controlled trial | Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans | Journal of endocrinological investigation | PMID 10195374 |
| 2009 | Randomised controlled trial | Determinants of GH-releasing hormone and GH-releasing peptide synergy in men | American journal of physiology. Endocrinology and metabolism | PMID 19240251 |
| 2007 | Randomised controlled trial | Peripheral estrogen receptor-alpha selectively modulates the waveform of GH secretory bursts in healthy women | American journal of physiology. Regulatory, integrative and comparative physiology | PMID 17686882 |
| 2007 | Clinical trial | Tripartite control of growth hormone secretion in women during controlled estradiol repletion | The Journal of clinical endocrinology and metabolism | PMID 17405836 |
| 1995 | Randomised controlled trial | Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature | Metabolism: clinical and experimental | PMID 7666796 |
This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-09.
Reported dosing ranges
No personal GHRP-2 dosing advice belongs in an article like this. Dosing depends on the exact compound, product quality, route, medical history, goals, medications, and clinician judgment.
The supplied citation records show that GHRP-2 has been studied in human endocrine settings, including a phase I pharmacokinetic and pharmacodynamic study in children and diagnostic growth-hormone testing in adults 1 6. The packet does not provide enough dose details to publish a patient-facing dosing range without risking misleading advice.
| Source type | What was studied or labelled | Dose information available from the supplied packet | How to use this information |
|---|---|---|---|
| Human phase I study | Pharmacokinetics and pharmacodynamics of GHRP-2 in children 1 | Specific dosing numbers are not provided in the supplied citation string. | Do not convert this into a personal dose. |
| Human diagnostic study | GHRP-2 test for adult growth-hormone deficiency 6 | Specific dosing numbers are not provided in the supplied citation string. | A diagnostic-test protocol is not the same as self-directed use. |
| Human endocrine stimulation studies | Growth-hormone stimulation and secretagogue-response studies 5 7 9 | Specific dosing numbers are not provided in the supplied citation string. | Ask a licensed clinician; do not rely on peptide calculators. |
| Online dosing calculators | Not a clinical source | No validated dose range is established by an online calculator. | Avoid using calculators as medical instructions. |
Why online peptide dosing calculators can be unsafe
Online calculators often skip the medical parts that matter: diagnosis, contraindications, lab context, sterile technique, product identity, and follow-up. A calculator cannot tell whether a hormone-pathway peptide is appropriate for you.
What to ask a licensed clinician before using any peptide
- What problem are we trying to address, and is a peptide the right tool?
- What human evidence supports this use, and what outcomes were actually measured?
- What side effects, contraindications, and monitoring matter for my health history?
- Where would the product come from, and how are sterility, identity, and impurities checked?
- What follow-up plan would be in place if symptoms or lab values change?
Legal status
Our regulatory log holds no confirmed federal action for GHRP-2. That means we have not found one with a primary source — not that none exists.
This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-09. See the full legal-status tracker for every compound we follow.
Safety
GHRP-2 safety cannot be fully characterized from the citation strings supplied for this page. Human trials are present in the record set, but the packet does not provide enough adverse-event detail to make a confident safety profile 1 2.
Because GHRP-2 acts in growth-hormone secretagogue pathways, patients should discuss hormone-related concerns with a clinician before considering any use. That includes pituitary disorders, abnormal growth-related symptoms, diabetes or glucose-control issues, cancer history, pregnancy, breastfeeding, fertility treatment, and other endocrine medications.
Supply quality is a separate safety issue. Products sold as “research use only” are not made for human care, and they may create risks around sterility, identity, impurity, concentration, storage, and contamination.
Side effects cannot be characterized from this packet
Some supplied records studied endocrine responses such as growth-hormone and cortisol secretion, but the citation strings do not provide enough adverse-effect detail for this page to list reliable frequency estimates 2 7. That uncertainty should not be treated as reassurance.
Hormone-pathway concerns to discuss with a clinician
Growth-hormone signaling touches many systems. A clinician may want to understand symptoms, medical history, medications, lab context, and whether a growth-hormone-related evaluation is appropriate before any peptide conversation.
Product-quality and contamination concerns
For any injectable or nasal peptide, product quality matters. Sterility, identity, concentration, storage conditions, and impurity testing are not small details; they are basic safety issues.
Interactions
No interaction profile can be established from the supplied GHRP-2 packet. The records include endocrine studies, but they do not provide a full drug-interaction database or patient-use safety guide 3 8.
This does not mean interactions are absent. It means this page cannot cite a complete interaction list from the supplied records.
Endocrine conditions
People with pituitary, adrenal, thyroid, or growth-hormone-axis conditions should be especially careful. GHRP-2 has been studied in endocrine testing contexts, including secondary adrenal failure and growth-hormone deficiency evaluations 3 6.
Cancer history or unexplained growth-related symptoms
Any history of cancer, unexplained swelling, headaches with vision changes, or other growth-related symptoms should be discussed with a clinician before considering a hormone-pathway peptide. The supplied records do not establish safety for these groups.
Diabetes, glucose control, and metabolic medications
Growth-hormone and ghrelin-related pathways can intersect with metabolism, appetite, and glucose regulation. The supplied records do not provide enough information to guide use with diabetes medications or weight-loss medications.
Pregnancy, breastfeeding, and fertility considerations
Pregnancy, breastfeeding, and fertility treatment change the risk-benefit discussion for hormone-related compounds. The supplied records do not establish safety for these situations.
How to obtain it legally
Chia does not offer GHRP-2. If you are trying to understand peptide access, the safe process starts with a licensed clinician evaluation, not a research-chemical vendor.
A clinician evaluation should review your goals, health history, medications, symptoms, and whether the peptide you are asking about is medically appropriate. A prescription, when clinically appropriate, is a medical decision; it is not guaranteed.
A licensed pharmacy pathway is meant to support identity, quality, labeling, and patient instructions. A research-chemical vendor is different: it is not a clinical relationship, does not provide medical follow-up, and may not meet standards needed for human use.
At Chia, we do not prescribe, sell, ship, or compound GHRP-2. We do offer related educational articles on growth-hormone secretagogues, including sermorelin, ipamorelin, and CJC-1295.
For treatments Chia actually offers, such as sermorelin, care starts with a 100% online health questionnaire and review by a licensed US provider. Chia offers sermorelin as injection, nasal spray, and tablets; plans for sermorelin injection currently start at $179/month. Medications are compounded by state-licensed US 503A pharmacies and shipped to the patient’s door when prescribed. Compounded medications are not FDA-approved.
| Question | GHRP-2 | Related Chia education or care |
|---|---|---|
| Does Chia offer it? | No. | Chia offers related education and offers sermorelin for eligible patients after clinician review. |
| What related article should I read first? | This GHRP-2 page. | Sermorelin growth-hormone peptide guide |
| What if I want to understand online access? | Start with clinician questions, not research-chemical vendors. | How to buy sermorelin online safely |
| What if I am comparing forms? | The supplied GHRP-2 packet does not support form-specific advice. | Oral sermorelin tablets vs injections |
FAQ
GHRP-2, also called pralmorelin, is described as a growth-hormone-releasing peptide and ghrelin-receptor agonist. Human studies in the supplied evidence set used it mainly to study hormone responses and diagnostic testing, not to prove everyday anti-aging or fitness benefits.
The supplied evidence does not prove that GHRP-2 builds muscle in everyday users. A hormone-stimulation study is not the same as a trial showing more strength or lean mass.
GHRP-2 is linked to ghrelin-receptor signaling, and ghrelin is involved in hunger biology. But this page cannot claim a predictable appetite effect for a specific person from the supplied records.
This article does not provide timing or dosing instructions. Peptide timing depends on the clinical reason, product, route, health history, and clinician judgment.
No. GHRP-2 and sermorelin are both discussed in growth-hormone-related peptide contexts, but they are different compounds. Sermorelin is a growth-hormone-releasing hormone analog; GHRP-2 is described as a growth-hormone-releasing peptide and ghrelin-receptor agonist.
No. Chia does not offer GHRP-2. Chia does offer related education and offers sermorelin for eligible patients after a licensed-provider evaluation.
No calculator can replace a medical evaluation. Online tools may miss contraindications, interactions, product-quality issues, sterile technique, and follow-up planning.
Do not use this article as dosing guidance. Consider speaking with a licensed clinician about what you bought, whether you used it, any symptoms, and whether any evaluation or monitoring is needed.
References
- 1.PMID 9543135 [clinical trial] Pihoker C, Kearns GL, French D, et al. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. The Journal of clinical endocrinology and metabolism. 1998.
- 2.PMID 20299490 [randomised controlled trial] Iranmanesh A, Bowers CY, Veldhuis JD. Secretagogue type, sex-steroid milieu, and abdominal visceral adiposity individually determine secretagogue-stimulated cortisol secretion. European journal of endocrinology. 2010.
- 3.PMID 27020037 [clinical trial] Arimura H, Hashiguchi H, Yamamoto K, et al. Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure. Endocrine journal. 2016.
- 4.PMID 21795635 [randomised controlled trial] Veldhuis JD, Bowers CY. Regulated recovery of pulsatile growth hormone secretion from negative feedback: a preclinical investigation. American journal of physiology. Regulatory, integrative and comparative physiology. 2011.
- 5.PMID 11004017 [clinical trial] Wideman L, Weltman JY, Patrie JT, et al. Synergy of L-arginine and GHRP-2 stimulation of growth hormone in men and women: modulation by exercise. American journal of physiology. Regulatory, integrative and comparative physiology. 2000.
- 6.PMID 17609397 [clinical trial] Chihara K, Shimatsu A, Hizuka N, et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. European journal of endocrinology. 2007.
- 7.PMID 23485864 [randomised controlled trial] Norman C, Miles J, Bowers CY, et al. Differential pulsatile secretagogue control of GH secretion in healthy men. American journal of physiology. Regulatory, integrative and comparative physiology. 2013.
- 8.PMID 10195374 [randomised controlled trial] Arvat E, Di Vito L, Lanfranco F, et al. Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans. Journal of endocrinological investigation. 1999.
- 9.PMID 19240251 [randomised controlled trial] Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. American journal of physiology. Endocrinology and metabolism. 2009.
- 10.PMID 17686882 [randomised controlled trial] Veldhuis JD, Keenan DM, Bowers CY. Peripheral estrogen receptor-alpha selectively modulates the waveform of GH secretory bursts in healthy women. American journal of physiology. Regulatory, integrative and comparative physiology. 2007.
- 11.PMID 17405836 [clinical trial] Veldhuis JD, Cosma M, Erickson D, et al. Tripartite control of growth hormone secretion in women during controlled estradiol repletion. The Journal of clinical endocrinology and metabolism. 2007.
- 12.PMID 7666796 [randomised controlled trial] Tuilpakov AN, Bulatov AA, Peterkova VA, et al. Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature. Metabolism: clinical and experimental. 1995.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if sermorelin is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
